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Background: Despite increasingly radical surgery for esophageal carcinoma, many patients still develop tumor
recurrence after operation. This study was designed to analyze the clinical and pathologic influencing factors of
early recurrence in patients with histological node-negative (pN0 stage) esophageal squamous cell carcinoma
(ESCC) after radical esophagectomy.
Methods: A retrospective study on 112 consecutive pN0 stage ESCC patients who underwent esophagectomy with
lymphadenectomy by the same surgical team from January 2004 to December 2010. There were 92 male and 20
female patients, aging from 36 to 80 years with a mean age of 60.3 years. The Cox proportional hazards model was
used to determine the independent risk factors for recurrence within 3 years after the operation.
Results: Recurrence was recognized in 45 patients (40.2%) within 3 years after operation. The median time to
tumor recurrence was 17.4 months. Locoregional recurrence was found in 38 patients (33.9%) and hematogenous
metastasis in 7 patients (6.3%). However, locoregional recurrence accounted for 84.4% of all relapse patients.
Recurrence closely correlated with tumor location, grade of differentiation, primary tumor stage (pT) and pathologic
stage (χ2 = 6.380 to 18.837, p < 0.05). The Cox multivariate analysis showed that upper/middle thoracic location
(OR = 1.092, p = 0.049) and pT3-4a stage (OR = 3.296, p = 0.017) were independent risk factors for postoperative
locoregional recurrence.
Conclusion: Locoregional recurrence was the most common recurrence pattern of patients with pN0 ESCC
within 3 years after operation. Upper/middle thoracic location and pT3-4a stage were independent risk factors
for locoregional recurrence of pN0 ESCC after radical esophagectomy.
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In China, the predominant pathologic type of esophageal
carcinoma is squamous cell carcinoma (ESCC), and
many tumors locate in the middle thoracic. The overall
5-year survival rate of patients with lymph node metas-
tasis (LNM) after surgical resection was only about 20%
[1], and most of these patients died of tumor relapse.
Recently, the therapeutic efficacy for ESCC had been
greatly improved due to the establishment and promotion* Correspondence: vwtfang@hotmail.com
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unless otherwise stated.of multidisciplinary treatment model [2]. However, even
for histological node-negative (pN0 stage) ESCC patients, a
large number of these patients still experienced recurrence
after operation [3]. So it was important to study the causes
and characteristics of recurrence when designing thera-
peutic strategies, including operative procedures and com-
bined therapies.
The purposes of this study were to explore the pattern
and time of recurrence after extended radical esophagec-
tomy with systemic lymphadenectomy, to identify the
prognostic factors responsible for recurrence, and to dis-
cuss therapeutic strategies that might be helpful to de-
crease recurrence and improve survival.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Patients
This study was approved by the Research Ethics
Committee of Shanghai Jiao Tong University School of
Medicine and all participants at the Shanghai Chest
Hospital gave written informed consent. A total of 112
consecutive pN0 stage ESCC patients who underwent
esophagectomy with lymphadenectomy by the same
surgical team from January 2004 to December 2010. The
inclusion criteria were as follows: (1) routine preoperative
esophageal endoscopy, a clear pathology of squamous cell
carcinoma, (2) assessment of tumor location by the upper
gastrointestinal barium swallow, (3) no evidence of tu-
mescent cervical or supraclavicular lymph node disease
was noted on physical examination, and a preoperative
computed tomograpy (CT) scan or cervical B ultrasound
study indicated no cervical or supraclavicular lymph
node metastasis, (4) positron emission tomography to
rule out distant metastasis, (5) no preoperative radiother-
apy and/or chemotherapy, (6) pathologically confirmed
lymph node-negative after operation, (7) all the patients
were R0 resection of pathologically confirmed, (8) all
the patients did not receive any adjuvant therapy be-
fore recurrence. Of all the patients, there were 92
men and 20 women, and the median age of 60.3 years
(range: 36–80 years). The tumor location and the TNM
classification were determined according to criteria estab-
lished by the Union for International Cancer Control
(UICC) in 2009 [4].
Surgical procedure
At operation the patient was placed in the 90° left lateral
decubitus position. After a right posterolateral thora-
cotomy, the chest was entered through the fifth inter-
costal space. The azygos vein arch was divided, and
the esophagus was dissected from the esophagogastric
junction to the apex of the chest. When the tumor in-
vasion obviously extended outside the esophagus, the
thoracic duct was routinely ligated above the diaphragm.
An upper midline abdominal incision was also made, and
the abdomen was explored. During mobilization of the
stomach, care was taken to preserve the right gastroepi-
ploic vessels and arcades. The left gastric artery and vein
were isolated and doubly ligated at their origin. The hiatus
was enlarged and the stomach was pulled into the chest.
An end-to-side esophagogastric anastomosis was per-
formed within the apex of the chest (above the azygos
vein) and the stomach was secured into the mediastinum
(Ivor-Lewis).When the tumor located in upper thoracic,
we will pull the stomach to neck by post-sternum tunnel
for anastomosis (McKeown).
According to a lymph node mapping system for esopha-
geal cancer (Japanese esophageal oncology group, JEOG)
(Figure 1), thoraco-abdominal 2-field lymphadenectomywas undertaken. Some patients were undertaken cervico-
thoraco-abdominal 3-field lymphadenectomy based
on the positive results of preoperative cervical ultra-
sonography. The fields of lymph node dissections were
as follows: 100, superficial cervical lymph nodes; 101,
cervical esophageal lymph nodes; 102, deep cervical
lymph nodes; 104, Supraclavicular lymph nodes; 105,
upper thoracic esophageal lymph nodes; 106, recurrent
laryngeal nerve lymph nodes; 107, subcarinal lymph
nodes; 108, middle thoracic esophageal lymph nodes;
109, hilar lymph nodes; 110, lower thoracic esophageal
lymph nodes; 111, diaphragmatic lymph nodes; 1, car-
dial lymph nodes (right); 2, cardial lymph nodes (left);
3, lesser curvature lymph nodes; 7, left gastric lymph
nodes.
Follow-up examinations
Patients were routinely accepted the first examination
at 3–4 weeks after the operation, examined at 3-month
intervals for 1 year and at 6-month intervals there-
after. During each follow-up visit, the patient under-
went a clinical evaluation, blood biochemistry examination
including tumor markers, and chest radiography. En-
doscopy, ultrasonography (US) of the neck and ab-
domen, and computed tomography (CT) of the neck,
thorax, and abdomen were performed at least once a
year. More selective investigations such as positron
emission tomography (PET), bone scintigraphy, and
Head-enhanced magnetic resonance imaging (MRI)
were carried out based on specific symptomatology,
clinical examination, and biochemical profile. Detec-
tion of a suspected recurrence at any one site was
followed by a thorough detailed investigation to con-
firm or refute the occurrence and to examine every other
site.
Definition of locoregional and hematogenous recurrence
The first recurrence was noted, and any additional re-
currence found within one month was considered to
have occurred simultaneously. These lesions were classi-
fied as locoregional (at the remaining esophagus, the
anastomotic site, or the mediastinum, cervical, supracla-
vicular and celiac axis lymph nodes) and hematogenous
(in the distant organs such as liver, lung, bone and
pleura, peritoneum) recurrence. Simultaneous locoregio-
nal and hematogenous recurrence was classified as a
hematogenous recurrence.
Statistical analysis
The SPSS 16.0 software package was used for data analysis.
Data were expressed as median with ranges (minimum-
maximum) or as percentages. The chi-square test was used
to evaluate differences in clinicopathologic features. The
Cox proportional hazards model was used to determine
Figure 1 Regional lymph node stations for staging esophageal cancer (JEOG).
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after the operation. Estimation of recurrence was cal-
culated with the Kaplan-Meier method, and the statisticaldifferences were analyzed with the log-rank test. A p value
of < 0.05 was considered statistically significant for all
procedures.
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112 patients were investigated and recurrence was rec-
ognized in 45 patients (40.2%) in the first 3 years after
operation. The median disease-free interval until recur-
rence was 17.4 months (range: 3.5-26.8 months). Of
these, 39 were men and 6 were women, and the median
age was 56 years (range: 39–76 years).
Pattern of recurrence
38 patients (33.9%) developed a locoregional recurrence;
7 patients (6.3%) developed a hematogenous recurrence,
including 2 patients (1.8%) with simultaneous locoregional
and hematogenous recurrence. However, locoregional re-
currence accounted for 84.4% of all relapse patients. The
relationship between clinicopathologic factors and recur-
rent disease was depicted in Table 1. There were significantTable 1 Clinical data of 112 pN0 ESCC patients undergoing
radical esophagectomy with lymphadenectomy
Variables Recurrence Statistic p Value
Positive Negtive
No. of patients 45 67 - -
Gender (M/F) 39/6 53/14 χ2 = 0.497 0.173
Age (years) 60 ± 5 61 ± 7 t = 4.877 0.782




Grade of differentiation χ2 = 6.380 0.043
Well (G1) 4 12
Moderately (G2) 9 22
Poorly (G3) 32 33





Pathological staging χ2 = 7.845 0.024
Stage I 1 20
Stage II 9 18
Stage III 31 26
Stage IIIA 4 3
Lymphadenectomy χ2 = 5.226 0.119
Two field 39 58
Three field 6 9
Intralmural metastasis χ2 = 3.593 0.336
Positive 4 0
Negtive 41 67differences in tumor location (p = 0.038), grade of differen-
tiation (p = 0.043), primary tumor stage (pT) (p = 0.006)
and pathologic stage (p = 0.024) between patients with re-
currence and those without recurrence.
The distribution of the sites of tumor recurrence
With respect to the locoregional tumor recurrence,
21 patients (15.3%) had recurrence in only cervical/
supraclavicular lymph nodes, 13 patients (34.2%) had re-
currence in only mediastinal lymph nodes, 6 (15.8%) in
only abdominal lymph nodes. In cases of hematogenous
recurrence, the main sites of recurrence were liver (6/7),
lung (2/7), and bone (1/7). There was no one had recur-
rence in brain, pleura and omentum in our patients
within 3 years after operation. Lymph node metastasis
occured earlier than hematogenous recurrence (Table 2
and Figure 2).
The multivariate analysis for locoregional recurrence
The multivariate analysis by the Cox proportional hazards
model demonstrated that Upper/middle thoracic loca-
tion (p = 0.049, OR = 1.092) and pT3-4a stage (p = 0.017,
OR = 3.296) were significant risk factors for locoregional
recurrence of pN0 ESCC after operation (Table 3). We did
not find a significant correlation between locoregional re-
currence and gender, histological differentiation, or lymph-
adenectomy style.
The recurrence curve in pN0 patients with different
pT stage was depicted in Figure 3 The log-rank test
showed that there was a significant difference among the
recurrence rates of these two groups (p = 0.000). TheTable 2 Site of locoregional and hematogenous
recurrence in 45 patients
Site of recurrence No. Percent (%) Time of recurrence3
(month)
Locoregional recurrence1 38
Cervical/supraclavicular node 21 55.3 14.9 (3.5 ~ 17.7)
Mediastinal node 13 34.2
upper 9 23.7 17.2 (4.8 ~ 23.2)
middle 3 7.9 19.2 (7.1 ~ 25.3)
lower 1 2.6 23.1
Abdominal node 6 15.8 18.4 (4.5 ~ 26.8)
Anastomotic 1 2.6 8.6
Hematogenous recurrence2 7
Liver 6 85.7 10.4 (5.2 ~ 20.4)
Lung 2 28.6 12.8 (9.4 ~ 16.2)
Bone 1 14.3 18.5
Others(brain/pleura/omentum) 0
1Three patients experienced locoregional recurrence at more than one site.
2Two patients experienced hematogenous recurrence at more than one site.
3Mean (range).
Figure 2 The comparison of occurrence time between
locoregional recurrence and hematogenous recurrence in
pN0 ESCC patients.
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acic location was higher than the rate of lower thoracic
location (p = 0.045) (Figure 4).
Discussion
The 7th edition UICC TNM staging of esophageal can-
cer (2009) increased cell differentiation (G) and histo-
logical type (H) as a staging reference factor, also the
pT3 stage (tumor invades adventitia) and pT4a stage
(resectable tumor invading pleura, pericardium, or
diaphragm) were distinguished [4]. With the wide appli-
cation of the new version of the standard staging for
esophageal cancer, the latest esophageal cancer treatment
guidelines by National Comprehensive Cancer Network
(NCCN) recommended for pN0 ESCC patients [5]:
(1) pT1-4aN0M0 patients with ESCC, follow-up and ob-
servation after operation; (2) pT1-2N0M0 patients with
adenocarcinoma, recommended follow-up and observa-
tion. However, some of the pT2N0M0 patients with high
risk (poorly differentiated, lymphatic invasion, perineural
invasion and <50 years of age), recommended post-
operative chemoradiation; (3) pT3-4aN0M0 patients with
adenocarcinoma were recommended postoperative che-
moradiation or follow-up.Table 3 The multivariate analysis for locoregional recurrence
Variable B SE
Tumor location
(upper/middle versus lower) 1.087 0.557
Grade of differentiation
(G3 versus G1 + 2) 0.478 0.235
Depth of invasion
(pT3-4a versus pT1-2) 1.193 0.250
B: regression coefficient; SE: standard error; Wald: wald value; OR: odds ratio; CI: conAs we can see, prophylactic postoperative adjuvant
therapy was not recommended for pT1-2N0M0 patients.
However, there was no uniform international standards
on whether pT3-4aN0M0 patients need postoperative
adjuvant therapy or not, and what specific treatment
should be chosen currently. It is worth noting that
China, as a country with high incidence of esophageal
cancer, nearly all of patients are squamous cell carcin-
oma. It is obviously different with the western countries
in which the main histology of esophageal cancer was
adenocarcinoma. Meanwhile, ESCC occur mostly in
upper and middle thoracic, but adenocarcinoma occur
mostly in lower thoracic. Whether from the perspective
of anatomical or histological analysis, ESCC is more easy
to have mediastinal lymph node metastasis even the
neck and peritoneal metastasis than adenocarcinoma.
Seen in this light, the foreign experience might not be
suitable for China. Therefore, to study the risk factors
for recurrence and metastasis in pN0 patients with
ESCC, following suitable adjuvant treatment had import-
ant clinical significance for reducing recurrence and im-
proving long-term survival.
Our cases showed that there was 40.2% of 112 pN0
ESCC patients had recurrence within 3 years after oper-
ation, with a median time (17.4 months) to recurrence,
similar to the results reported in the literature [6]. Uni-
variate analysis showed that recurrence closely correlated
with tumor location, grade of differentiation, primary
tumor stage (pT) and pathologic stage. The COX propor-
tional hazards regression multivariate analysis confirmed
that upper/middle thoracic location and pT3-4a stage
were independent risk factors for postoperative locoregio-
nal recurrence. The pT stage (Wald = 22.731; OR = 3.296)
was the most important risk factor on recurrence and me-
tastasis of pN0 ESCC according to the Wald value. With
increasing pT stage, the chance of recurrence and metasta-
sis in pN0 esophageal cancer patients also increased sig-
nificantly. The reason was that esophagus lacks serosa,
once the tumor invades adventitia, not only the submuco-
sal longitudinal lymphatic vessels but also lateral medias-
tinal lymphatic vessels originating from the muscle layer
contribute greatly to the LNM [7]. In present study, theof pN0 ESCC
Wald pValue OR 95 % CI
3.808 0.049 1.092 1.088 ~ 2.383
4.143 0.068 1.613 0.690 ~ 1.551
22.731 0.017 3.296 2.019 ~ 5.381
fidence interval.
Figure 3 Recurrence curve for the patients with different pT stage.
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cance with tumor recurrence might be due to small num-
ber of cases, but the p value (0.068) was close to 0.05. In
addition, four patients with pathologically confirmed the
presence of intralmural metastasis, three of them had cer-
vical lymph node recurrence 2 years after operation and
another appeared residual esophageal tumor recurrence
1 year after operation. It was suggesting that intralmural
metastasis might be an important risk factor for recur-
rence of pN0 ESCC. Therefore, taking into account the
possibility of multi-center origin in esophageal cancer and
intralmural metastasis, we have to do the following in op-
eration: (1) resection with sufficient length of esophagus;
(2) complete resection of the lesion and the surroundingFigure 4 Recurrence curve for the patients with different tumor locatinvolved structures; (3) radical elimination of lymphatic
tissue.
In the present study, the most common recurrence
pattern of pN0 patients with ESCC after operation was
locoregional recurrence (38/45, 84.4%) and LNM (37/38,
97.4%) was the main form, mainly in the cervicothoracic
junction. Therefore, the cervicothoracic junction was the
key position for preventing recurrence of pN0 patients
with ESCC after operation. In addition, the difference of
recurrence between two-field (thoracic and abdominal)
lymph node dissections and three-field (cervical, thoracic
and abdominal) lymph node dissections was not signifi-
cant in our study. However, the literature had reported
that three-field lymph node dissections could reduceion.
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sible explanations were: Firstly, patients with pN0 ESCC
might not need the three-field lymph node dissections;
Secondly, there were statistical deviation due to small
number of patients were given three-field lymph node
dissections in this group, and this study was a retro-
spective analysis. Cervical B ultrasound was helpful to
the diagnosis of LNM in cervicothoracic junction [9],
combined with preoperative CT scan of chest/abdomen
and positron emission tomography, establishing an ac-
curate clinical staging was helpful to select the patients
who do need three-field lymph node dissections [10].
We also took into account: (1) there were many import-
ant organs, large vessels in cervicothoracic junction and
the region of recurrent laryngeal nerve was a relatively
difficult position for systemic lymph node dissections
because of higher requirements of surgical techniques;
(2) three-field lymph node dissections had to face the
bottleneck which can not further improve the long-term
survival obviously. So, the postoperative radiotherapy
and/or chemotherapy might be a good alternative.
Our data did not find independent risk factors for pN0
ESCC patients with hematogenous metastasis, suggest-
ing that hematogenous metastasis was mostly influenced
by the biological behavior of tumor cell rather than
depth of tumor invasion, LNM and differentiation [11].
Thus, it was necessary to carry out prospective clinical
study for evaluating whether vascular invasion, lymph-
atic invasion, and perineural invasion and so on were re-
lated with hematogenous metastasis or not.Conclusions
In summary, we have confirmed that locoregional recur-
rence was the most common recurrence pattern of pa-
tients with pN0 ESCC within 3 years after operation.
Upper/middle thoracic location and pT3-4a stage were
independent risk factors for locoregional recurrence of
pN0 ESCC after radical esophagectomy. For these high-
risk groups, prophylactic radiotherapy for bilateral supra-
clavicular and upper mediastinal might be helpful to
reduce the recurrence rate.
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